These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Delavirdine gains approval as second NNRTI for anti-HIV combination regimens.
    Journal: Crit Path AIDS Proj; 1997; (No 32):29-30. PubMed ID: 11364439.
    Abstract:
    The Food and Drug Administration (FDA) has granted accelerated approval for delavirdine (Rescriptor) for use in combination with other anti-HIV drugs. The non-nucleoside reverse transcriptase inhibitor (NNRTI) inhibits the virus through binding with the enzyme and may be synergistic with AZT and ddC. Interim test results have reported viral load reductions with combination therapy. There is no data related to survival or incidence of AIDS-related illnesses. There are few side effects associated with the drug, and its cost is significantly below that of protease inhibitors.
    [Abstract] [Full Text] [Related] [New Search]